An in vitro pharmacodynamic system has been successfuly adapted to simulate in vivo antimicrobial pharmacokinetics under anaerobic conditions. This system was used to perform time-kill kinetic studies which were designed to compare the activity of temafloxacin to ciprofloxacin and cefotetan against two strains of Bacteroides fragilis (ATCC 25285 and ATCC 23745 fragilis. Ciprofloxacin was not bactericidal (<3 log10 unit decline in bacterial numbers) to either strain of B.
manufacturer because of toxicity issues. Although the release of newer fluoroquinolones that possess significant activity against anaerobic bacteria does not appear imminent, the time-kill studies performed in this study demonstrate that further research is warranted in the development of fluoroquinolones which possess significant antianaerobic activity.
Bacteroides fragilis is an important human pathogen in intra-abdominal and gynecologic infections. Antimicrobial regimens for infections that involve B. fragilis have generally been limited to certain ,B-lactams, clindamycin, chloramphenicol, or metronidazole. The prevalence of severe adverse reactions to chloramphenicol and the development of significant resistance among B. fragilis strains to clindamycin have driven the search for safe and effective therapeutic alternatives. All of the currently available fluoroquinolones possess excellent activity against aerobic and facultative gram-negative bacteria. Temafloxacin, however, has been shown to have significant in vitro activity against anaerobic bacteria while retaining excellent activity against most members of the Enterobacteriaceae (6, 9, 17) . The in vitro evaluation of the activity of the fluoroquinolones against anaerobic bacteria has been based on standardized MIC testing. MIC testing methods possess some inherent restrictions that limit the researcher's ability to optimally evaluate the activity of a drug in vitro.
The purpose of this study was to use an in vitro pharmacodynamic system to evaluate the activity of temafloxacin, ciprofloxacin, and cefotetan against two strains of B. fragilis. Through time-kill curve analysis, this system can exploit the pharmacokinetic and pharmacodynamic differences between drugs and thereby evaluate their relative in vitro efficacies.
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MATERIALS AND METHODS
In vitro pharmacodynamic anaerobic system. The in vitro pharmacodynamic anaerobic system (Fig. 1) is a modification of the system previously described by Garrison et al. (7) . The in vitro pharmacodynamic system was placed within a Bactron IV anaerobic chamber (Sheldon Manufacturing, Cornelius, Oreg.) and consisted of each of the following: a glass vessel (volume, 1 liter) with inflow and outflow ports, connective silicone tubing (Masterflex L/S thin-wall tubing; Cole-Parmer, Chicago, Ill.), a Masterflex peristaltic pump (Cole-Parmer Instrument Co.), a fresh media reservoir, a stir/hot plate (Nuovo II; BarnsteadlThermolyne Corp., Dubuque, Iowa), a magnetic stir bar, and a thermometer.
The antimicrobial agent was injected into the system as a bolus so that targeted peak concentrations could be produced. By using the peristaltic pump, antimicrobial agentfree medium was pumped into the system such that an equal volume of antimicrobial agent-containing medium was displaced. This resulted in the simulation of a first-order, one-compartment pharmacokinetic process.
An anaerobic environment was created by placing the pharmacodynamic system within a Bactron IV anaerobic chamber (Sheldon Manufacturing). The chamber operates with anaerobic mixed gas of 5% hydrogen, 10% carbon dioxide, and 85% nitrogen. Positive pressure is maintained unit decline in bacterial numbers, (ii) total logarithmic decline in bacterial numbers; and (iii) total extent of regrowth. Because of small sample sizes, inferential statistics were not applied to these data. We believe that the data are best represented by being given in their entirety. Temafloxacin, cefotetan, and ciprofloxacin concentrations were quantified by using previously validated high-pressure liquid chromatography methods (10, 12, 20) . The temafloxacin assay was linear for five successive serial dilutions ranging from 0.65 to 20 ,ug/ml (r2 = 0.998). The lower limit of quantification was 0.5 ,ug/ml, and the intraday coefficient of variation was 1.6%. The cefotetan assay was linear for five successive serial dilutions ranging from 0.65 to 80.33 ,ug/ml (r2 = 0.997). The lower limit of quantification was 0.65 ,g/ml, and the intraday coefficient of variation was 5.64%. The ciprofloxacin assay was linear for five successive dilutions ranging from 0.5 to 20 ,ug/ml (r2 = 0.999). The lower limit of quantification was 0.5 ,ug/ml, and the intraday CV coefficient of variation was 7.4%.
RESULTS
Susceptibility testing. MICs of temafloxacin, ciprofloxacin, and cefotetan are shown for the study strains in Table 1 . Preexposure MICs of temafloxacin (0.5 and 1 ,g/ml) were lower than those of ciprofloxacin (2 and 4 ug/ml) for strains ATCC 25285 and ATCC 23745, respectively. MICs of cefotetan were 8 ,ug/ml for both strains. MBCs were within two dND, no data.
serial dilutions of MICs for each antimicrobial agent-bacterium combination. MICs of temafloxacin for regrowth isolates from time-kill studies were significantly higher than those measured prior to antimicrobial exposure. MICs of temafloxacin increased by four dilutions (from 0.5 to 8 ,ug/ml) for strain ATCC 25285 and by three to four dilutions for strain ATCC 23745. MICs of ciprofloxacin for regrowth isolates of strain ATCC 25285 increased only slightly (by one to two dilutions), and MICs of ciprofloxacin to strain ATCC 23745 remained unchanged. MICs of cefotetan to regrowth isolates remained unchanged from those of preexposed strains.
Antibiotic carryover. Antibiotic carryover was not evident, since colony counts from, drug-exposed plates did not differ significantly from those of growth control plates (P < 0.01).
Pharmacokinetic analysis. Antimicrobial concentrationversus-time data are summarized in Table 2 Table 2 . Bacteria demonstrated exponential growth during each growth control experiment, as indicated by a satisfactory fit to a log-linear relationship (r = 0.99). Ciprofloxacin was not bactericidal (<3 log1o unit decline in bacterial numbers) against either strain. Ciprofloxacin produced average total logarithmic declines of 1.2 and 2.9 for strains ATCC 23745 and ATCC 25285, respectively. Temafloxacin produced similar total logarithmic declines compared with cefotetan for each strain. Temafloxacin produced average total logarithmic declines of 4.1 and .4.5, whereas cefotetan produced total logarithmic declines of .4.5 and >4.5 for B. fragilis ATCC 23745 and ATCC 25285, respectively. Declines of more than 4.5 logarithmic units could not be determined since 3 x 102 CFU/ml was the lower limit of accuracy.
Of the three antimicrobial agents tested, temafloxacin produced the most rapid 3 log1o unit decline of ATCC 25285 and was equal to cefotetan in this respect for strain ATCC 23745. Average times to 3 log1o unit declines of B. fragilis ATCC 25285 were 2 and 4 h, whereas those of B. fragilis ATCC 23745 were 4 and 4 h, for temafloxacin and cefotetan, respectively.
Bacterial regrowth was detected in each experiment. Bacterial populations exposed to cefotetan produced the least regrowth (4.3 log10 CFU/ml for each strain), whereas temafloxacin experiments resulted in slightly more regrowth (5.5 and 5.7 log1o CFU/ml) and ciprofloxacin experiments resulted in the most regrowth (8.9 and 9.2 log1o CFU/ml). 
DISCUSSION
Time-kill curve analysis revealed that temafloxacin was rapidly bactericidal for B. fragilis and that it performed comparably to the control drug, cefotetan, in terms of time to 3 log1o unit decline and total logarithmic reduction. Other investigators have observed that peak-to-MIC ratios are predictive of the rate and extent to which quinolones kill bacteria that grow aerobically (2, 4, 5) . In the present study, temafloxacin peak-to-MIC ratios of approximately 10 and 5 resulted in logarithmic reductions of more than 4.5 (ATCC 25285) and 4.1 (ATCC 23745) log1o CFU/ml. Ciprofloxacin peak-to-MIC ratios of approximately 2 and 1 resulted in total logarithmic reductions of 2.9 (ATCC 25285) and 1.2 (ATCC 23745) log1o CFU/ml. Although the data from the present study are limited, these limited data would suggest that peak-to-MIC ratios are predictive of the rate and extent to which quinolones kill B. fragilis.
Bacterial exposure to the fluoroquinolones resulted in more bacterial regrowth than did exposure to cefotetan. Since these were single-dose experiments, we can only speculate about whether a second dose of antibiotic would have had an effect on the regrowing bacteria. Blaser et al. (2) observed that bacterial regrowth occurred in the presence of enoxacin within 24 h unless the peak-to-MIC ratio exceeded 8:1. McGrath et al. (14) , however, observed that the regrowth of Pseudomonas aeruginosa could not be prevented by multiple doses of ciprofloxacin that exceeded peak-to-MIC ratios of 8:1. Still other investigators (13) (5) . Therefore, the bulk of available information would suggest that bacterial regrowth in neutropenic models of infection is most effectively prevented by using two antibiotics that involve different mechanisms of action. It is important to note, however, that the studies cited above were not done with B. fragilis, and therefore the application of these other observations to the present study is at best speculative.
Bacterial populations which regrew in the presence of temafloxacin became more resistant in terms of MIC, whereas cefotetan and ciprofloxacin postexposure MICs remained unchanged. Bacterial regrowth during exposure to a fluoroquinolone has been described by McGrath et al. (14) . These investigators exposed P. aeruginosa to multiple doses of temafloxacin and found that the antimicrobial agent produced less killing and the bacteria regrew more readily with the administration of further doses. When the susceptibilities of the regrowth isolates were tested with graded dilutions of antibiotic-containing agar, the bacteria which regrew were found to be less sensitive than the original starting population. The investigators attributed this increase to a selection of temafloxacin-resistant subpopulations of P. aeruginosa.
The presence of selection-resistant subpopulations appears to be the most plausible explanation for the regrowth of B. fragilis seen in the present study. It is interesting, however, that the MICs of temafloxacin for regrowth isolates increased, whereas those of ciprofloxacin and cefotetan remained relatively unchanged. A half-life of 8 h was simulated for temafloxacin, whereas half-lives of 4 h were simulated for ciprofloxacin and cefotetan. Consequently, at the end of 24-h experiments, concentrations of temafloxacin, ciprofloxacin, and cefotetan were approximately 0.6, 0.07, and 1.5 ,ug/ml, respectively. Therefore, the most plausible explanation may be that more selective pressure was maintained by the higher residual concentrations of temafloxacin and less selective pressure was maintained by residual concentrations of ciprofloxacin and cefotetan. Support for this explanation can be found in work done by Gerber et al. (8) and McGrath et al. (13) . Each of these groups of investigators found that aminoglycoside-resistant subpopulations of P. aeruginosa "vanished" after the selective pressure of the aminoglycoside was removed. The investigators concluded that the resistant subpopulations were overcome by more susceptible, faster-growing subpopulations when the aminoglycoside pressure was removed.
Temafloxacin is a fluoroquinolone with established in vitro activity against B. fragilis (6, 9, 17) . However, this product was removed from the market by its manufacturer because of toxicity issues surrounding its postmarketing use (3). Other fluoroquinolones that are currently being developed are known to possess significant in vitro activity against anaerobic bacteria (11, 19) . Although this study was performed with only two strains of one species of anaerobic bacteria, these data indicate that further research is warranted in the development of fluoroquinolones which possess anaerobic activity.
As further information about new fluoroquinolones becomes available, members of this class of antimicrobial agents may become valuable tools for use in the treatment of anaerobic infections and, in particular, for use as "switch therapy" as patients with mixed or anaerobic infections are discharged from the hospital for continued antimicrobial therapy as outpatients. An oral form of treatment that is effective against a broad spectrum of aerobic and anaerobic bacteria would be extremely desirable for selected infections that would otherwise require long durations of treatment with intravenous antibiotics.
